Bisindolylmaleimide IV
(Synonyms: 双吲哚马来酰亚胺IV,Arcyriarubin A,BIM IV) 目录号 : GC14716
Bisindolylmaleimide IV 是一种强效的细胞膜透过性蛋白激酶C(PKC)抑制剂,其IC50值为0.1-0.55μM。
Cas No.:119139-23-0
Sample solution is provided at 25 µL, 10mM.
Bisindolylmaleimide IV is a potent cell-permeable inhibitor of protein kinase C (PKC) with IC50 values are 0.1- 0.55μM[1]. Bisindolylmaleimide IV inhibits the cAMP-dependent protein kinase (PKA) with IC50 ranging from 3.1-11.8μM[2]. Bisindolylmaleimide IV is primarily used in research related to cancer biology[3], cardiovascular diseases[4], and diabetes, particularly in studies investigating PKC-mediated signaling pathways and their impact on cellular functions[5].
Bisindolylmaleimide IV (20μM) down-regulates cellular caspase 8 (FLICE)-like inhibitory protein (c-FLIPL) expression and facilitates CD95-mediated apoptosis in monocyte-derived dendritic cells[6]. Bisindolylmaleimide IV (0.1-100μM) inhibits the release of reactive oxygen species (ROS) from human neutrophils stimulated by agents such as IL-3, phorbol-12-myristate-13-acetate (PMA), and sodium fluoride in a dose-dependent manner[7].
References:
[1]. Toullec D, Pianetti P, Coste H, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991 Aug 25;266(24):15771-81. PMID: 1874734.
[2]. Fabre S, Prudhomme M, Rapp M. Protein kinase C inhibitors; structure-activity relationships in K252c-related compounds. Bioorg Med Chem. 1993 Sep;1(3):193-6. doi: 10.1016/s0968-0896(00)82121-5. PMID: 8081852.
[3]. Pajak B, Orzechowska S, Gajkowska B, Orzechowski A. Bisindolylmaleimides in anti-cancer therapy - more than PKC inhibitors. Adv Med Sci. 2008;53(1):21-31. doi: 10.2478/v10039-008-0028-6. PMID: 18635421.
[4]. Silnitsky S, Rubin SJS, Zerihun M, Qvit N. An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases. Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600. PMID: 38139428; PMCID: PMC10743896.
[5].Anderson PW, McGill JB, Tuttle KR. Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2007 Sep;16(5):397-402. doi: 10.1097/MNH.0b013e3281ead025. PMID: 17693752.
[6]. Willems F, Amraoui Z, Vanderheyde N, et al. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood. 2000 Jun 1;95(11):3478-82. PMID: 10828032.
[7]. Krämer HJ, Kessler D, Hipler UC, et al. Pityriarubins, novel highly selective inhibitors of respiratory burst from cultures of the yeast Malassezia furfur: comparison with the bisindolylmaleimide arcyriarubin A. Chembiochem. 2005 Dec;6(12):2290-7. doi: 10.1002/cbic.200500163. PMID: 16252297.
Bisindolylmaleimide IV是一种强效的细胞膜透过性蛋白激酶C(PKC)抑制剂,其IC50值为0.1-0.55μM[1]。Bisindolylmaleimide IV还能抑制cAMP依赖性蛋白激酶(PKA),其IC50值为3.1-11.8μM[2]。Bisindolylmaleimide IV主要用于癌症生物学[3]、心血管疾病[4]和糖尿病的研究,特别是在研究PKC介导的信号通路及其对细胞功能的影响方面[5]。
Bisindolylmaleimide IV(20μM)可下调细胞型 caspase 8(FLICE)样抑制蛋白(c-FLIPL)的表达,并促进CD95介导的单核细胞来源的树突状细胞凋亡[6]。Bisindolylmaleimide IV(0.1-100μM)能够以剂量依赖的方式抑制由IL-3、佛波醇-12-肉豆蔻酸-13-乙酸酯(PMA)和氟化钠等刺激剂诱导的中性粒细胞活性氧(ROS)释放[7]。
References:
[1]. Willems F, Amraoui Z, Vanderheyde N, et al. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood. 2000 Jun 1;95(11):3478-82. PMID: 10828032.
Cas No. | 119139-23-0 | SDF | |
别名 | 双吲哚马来酰亚胺IV,Arcyriarubin A,BIM IV | ||
化学名 | 3,4-di-1H-indol-3-yl-1H-pyrrole-2,5-dione | ||
Canonical SMILES | O=C1NC(=O)C(=C1c1c[nH]c2ccccc12)c1c[nH]c2ccccc12 | ||
分子式 | C20H13N3O2 | 分子量 | 327.3 |
溶解度 | ≤20mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.0553 mL | 15.2765 mL | 30.553 mL |
5 mM | 0.6111 mL | 3.0553 mL | 6.1106 mL |
10 mM | 0.3055 mL | 1.5277 mL | 3.0553 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet